DCAI Dialysis of America (MM)

Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Dialysis Corporation of America, Inc. (“DCA” or the “Company”) (Nasdaq:DCAI) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by U.S. Renal Care, Inc. (“USRC”) in a transaction valued at approximately $112 million.

Under the proposed agreement, USRC will make a cash tender offer of $11.25 per share for each share of DCA common stock outstanding. In addition, directors and executive officers of DCA holding approximately 23% of DCA’s outstanding common stock have entered into agreements to, among other things, tender their shares into the tender offer. The investigation concerns whether DCA’s board of directors failed to adequately shop the Company and obtain the best price possible for DCA’s shareholders before entering into the agreement with USRC. On March 10, 2010, the Company announced its fourth quarter and year end 2009 financial results wherein it announced both a 14% increase in operating revenues and a 9% increase in operating income in 2009. Stephen Everett, DCA’s President and CEO, commented, “We are very pleased with our company's performance throughout 2009.”

If you own the common stock of DCA and purchased your shares before April 13, 2010, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware, by telephone at (888) 969-4242, or by e-mail to info@rigrodskylong.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Dialysis OF America (NASDAQ:DCAI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Dialysis OF America (NASDAQ:DCAI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024